JPH021126B2 - - Google Patents

Info

Publication number: JPH021126B2
Authority: JP; Japan
Prior art keywords: composition; salt; pharmaceutically acceptable; heparin; component
Prior art date: 1979-11-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP55159376A

Other languages

English (en)

Japanese (ja)

Other versions

JPS5686116A (en

Inventor

Harutoman Fuorukaa

Otsuto Kaaruuhaintsu

Patsuto Ruudoitsuhi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sandoz AG

Original Assignee

Sandoz AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-11-12

Filing date

1980-11-11

Publication date

1990-01-10

1980-11-11 Application filed by Sandoz AG filed Critical Sandoz AG

1981-07-13 Publication of JPS5686116A publication Critical patent/JPS5686116A/ja

1990-01-10 Publication of JPH021126B2 publication Critical patent/JPH021126B2/ja

Status Granted legal-status Critical Current

Links

239000000203 mixture Substances 0.000 claims description 49
239000000243 solution Substances 0.000 claims description 41
150000003839 salts Chemical class 0.000 claims description 29
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 23
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 17
229960002897 heparin Drugs 0.000 claims description 16
229920000669 heparin Polymers 0.000 claims description 16
238000000034 method Methods 0.000 claims description 16
239000004480 active ingredient Substances 0.000 claims description 15
FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 claims description 14
239000002253 acid Substances 0.000 claims description 13
150000001875 compounds Chemical class 0.000 claims description 13
238000002347 injection Methods 0.000 claims description 11
239000007924 injection Substances 0.000 claims description 11
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 claims description 9
230000003444 anaesthetic effect Effects 0.000 claims description 8
229960004704 dihydroergotamine Drugs 0.000 claims description 8
229960001413 acetanilide Drugs 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
239000001257 hydrogen Substances 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 6
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
239000002904 solvent Substances 0.000 claims description 6
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 5
239000004615 ingredient Substances 0.000 claims description 5
238000011282 treatment Methods 0.000 claims description 5
239000003708 ampul Substances 0.000 claims description 4
159000000007 calcium salts Chemical class 0.000 claims description 4
229960004194 lidocaine Drugs 0.000 claims description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
LIWOWASNSWUKPF-UHFFFAOYSA-N Tolycaine hydrochloride Chemical compound Cl.CCN(CC)CC(=O)NC1=C(C)C=CC=C1C(=O)OC LIWOWASNSWUKPF-UHFFFAOYSA-N 0.000 claims description 3
125000000217 alkyl group Chemical group 0.000 claims description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
229960001290 butanilicaine Drugs 0.000 claims description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
159000000000 sodium salts Chemical class 0.000 claims description 3
150000005846 sugar alcohols Polymers 0.000 claims description 3
ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 claims description 3
SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 claims description 2
OHJKXVLJWUPWQG-PNRHKHKDSA-N Heparinsodiumsalt Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](O)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H](C(O)=O)O1 OHJKXVLJWUPWQG-PNRHKHKDSA-N 0.000 claims description 2
YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical class CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 claims description 2
238000004090 dissolution Methods 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
WROUIBGUWODUPA-UHFFFAOYSA-N 2-(butylamino)-n-(2-chloro-6-methylphenyl)acetamide;hydrochloride Chemical compound [Cl-].CCCC[NH2+]CC(=O)NC1=C(C)C=CC=C1Cl WROUIBGUWODUPA-UHFFFAOYSA-N 0.000 claims 1
239000000306 component Substances 0.000 claims 1
239000011261 inert gas Substances 0.000 claims 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 7
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
ADYPXRFPBQGGAH-UMYZUSPBSA-N dihydroergotamine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-UMYZUSPBSA-N 0.000 description 6
238000003756 stirring Methods 0.000 description 6
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
239000011734 sodium Substances 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 3
VWYQKFLLGRBICZ-UHFFFAOYSA-N butanilicaine Chemical compound CCCCNCC(=O)NC1=C(C)C=CC=C1Cl VWYQKFLLGRBICZ-UHFFFAOYSA-N 0.000 description 3
NQRDVLDEYJYWQR-SZGCSELGSA-N dihydroergovaline Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C)=C3C2=CNC3=C1 NQRDVLDEYJYWQR-SZGCSELGSA-N 0.000 description 3
239000007789 gas Substances 0.000 description 3
YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
229960004393 lidocaine hydrochloride Drugs 0.000 description 2
-1 maleate salt Chemical class 0.000 description 2
239000012528 membrane Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
DHMNSVVFIZNPGX-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;hexahydrate Chemical compound O.O.O.O.O.O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O DHMNSVVFIZNPGX-UHFFFAOYSA-N 0.000 description 1
SKOVXWGCQMGKQB-UHFFFAOYSA-N 2-amino-n,n-diphenylacetamide Chemical class C=1C=CC=CC=1N(C(=O)CN)C1=CC=CC=C1 SKOVXWGCQMGKQB-UHFFFAOYSA-N 0.000 description 1
241001649081 Dina Species 0.000 description 1
206010050902 Postoperative thrombosis Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
RXDLGFMMQFNVLI-UHFFFAOYSA-N [Na].[Na].[Ca] Chemical compound [Na].[Na].[Ca] RXDLGFMMQFNVLI-UHFFFAOYSA-N 0.000 description 1
150000008061 acetanilides Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
229940035674 anesthetics Drugs 0.000 description 1
239000004019 antithrombin Substances 0.000 description 1
FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
229960002242 chlorocresol Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000013066 combination product Substances 0.000 description 1
229940127555 combination product Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
239000006104 solid solution Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/02—Ergot alkaloids of the cyclic peptide type

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

JP15937680A 1979-11-12 1980-11-11 Stable solution of hydrogenated ergot alkaloids Granted JPS5686116A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19792945636 DE2945636A1 (de)	1979-11-12	1979-11-12	Stabile loesungen von hydrierten ergotalkaloiden bzw. ihren salzen und heparin bzw. seinen salzen sowie verfahren zu deren herstellung

Publications (2)

Publication Number	Publication Date
JPS5686116A JPS5686116A (en)	1981-07-13
JPH021126B2 true JPH021126B2 (da)	1990-01-10

Family

ID=6085779

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP15937680A Granted JPS5686116A (en)	1979-11-12	1980-11-11	Stable solution of hydrogenated ergot alkaloids

Country Status (22)

Country	Link
EP (1)	EP0028813B1 (da)
JP (1)	JPS5686116A (da)
AT (1)	AT371997B (da)
AU (1)	AU535357B2 (da)
BE (1)	BE886008A (da)
CA (1)	CA1165692A (da)
CH (1)	CH650930A5 (da)
CY (1)	CY1332A (da)
DE (2)	DE2945636A1 (da)
DK (1)	DK155144C (da)
FI (1)	FI72045C (da)
GB (1)	GB2062468B (da)
GR (1)	GR72128B (da)
HK (1)	HK40386A (da)
HU (1)	HU183244B (da)
IE (1)	IE50372B1 (da)
IL (1)	IL61447A (da)
KE (1)	KE3623A (da)
MY (1)	MY8500165A (da)
PH (1)	PH22800A (da)
PT (1)	PT72041B (da)
ZA (1)	ZA807005B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3227122A1 (de) *	1982-07-20	1984-01-26	Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim	Stabile loesungen von mutterkornalkaloiden
CH656533A5 (de) *	1982-12-10	1986-07-15	Sandoz Ag	Therapeutisches praeparat enthaltend hydrierte ergotalkaloide und niedermolekulares heparin.
DE3432661A1 (de) *	1984-09-05	1986-03-06	Albert Prof. Dr. 6907 Nußloch Landsberger	Carcinom-therapeutikum
AT381232B (de) *	1985-05-13	1986-09-10	Kwizda Fa F Johann	Verfahren zur herstellung stabiler fluessiger loesungen von ergolinderivaten
TW200402307A (en) *	2002-06-20	2004-02-16	Novartis Consumer Health Sa	Nasal composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2735587A1 (de) *	1977-08-06	1979-02-15	Sandoz Ag	Stabile loesungen und verfahren zu deren herstellung
DE2625403A1 (de) *	1976-06-05	1977-12-08	Sandoz Ag	Neue therapeutische mischung und verfahren zu deren herstellung
DE2809618A1 (de) *	1978-03-06	1979-09-20	Sandoz Ag	Neues therapeutisches praeparat und verfahren zu dessen herstellung
DE2555481C3 (de) *	1975-12-10	1985-10-03	Sandoz-Patent-GmbH, 7850 Lörrach	Herstellung stabiler Tropflösungen von hydrierten Ergotalkaloiden
DE2945677A1 (de) *	1979-11-12	1981-05-21	Sandoz-Patent-GmbH, 7850 Lörrach	Verwendung eines zweikammersystems zur verabreichung einer antithrombotischen mischung

1979
- 1979-11-12 DE DE19792945636 patent/DE2945636A1/de not_active Withdrawn
1980
- 1980-11-03 BE BE1/10018A patent/BE886008A/fr not_active IP Right Cessation
- 1980-11-04 CH CH8192/80A patent/CH650930A5/de not_active IP Right Cessation
- 1980-11-05 FI FI803456A patent/FI72045C/fi not_active IP Right Cessation
- 1980-11-06 EP EP80106843A patent/EP0028813B1/de not_active Expired
- 1980-11-06 DE DE8080106843T patent/DE3068719D1/de not_active Expired
- 1980-11-10 GB GB8036009A patent/GB2062468B/en not_active Expired
- 1980-11-10 CA CA000364330A patent/CA1165692A/en not_active Expired
- 1980-11-10 DK DK477880A patent/DK155144C/da not_active IP Right Cessation
- 1980-11-10 AT AT0550480A patent/AT371997B/de not_active IP Right Cessation
- 1980-11-10 GR GR63321A patent/GR72128B/el unknown
- 1980-11-10 IL IL61447A patent/IL61447A/xx unknown
- 1980-11-10 PH PH24834A patent/PH22800A/en unknown
- 1980-11-10 CY CY1332A patent/CY1332A/xx unknown
- 1980-11-10 PT PT72041A patent/PT72041B/pt unknown
- 1980-11-10 HU HU802692A patent/HU183244B/hu not_active IP Right Cessation
- 1980-11-11 JP JP15937680A patent/JPS5686116A/ja active Granted
- 1980-11-11 IE IE2340/80A patent/IE50372B1/en unknown
- 1980-11-11 AU AU64265/80A patent/AU535357B2/en not_active Ceased
- 1980-11-12 ZA ZA00807005A patent/ZA807005B/xx unknown
1985
- 1985-12-30 MY MY165/85A patent/MY8500165A/xx unknown
1986
- 1986-04-14 KE KE3623A patent/KE3623A/xx unknown
- 1986-05-29 HK HK403/86A patent/HK40386A/xx unknown

Also Published As

Publication number	Publication date
AU6426580A (en)	1981-05-21
PH22800A (en)	1988-12-12
EP0028813A3 (en)	1982-08-25
HU183244B (en)	1984-04-28
FI803456L (fi)	1981-05-13
CA1165692A (en)	1984-04-17
KE3623A (en)	1986-05-16
PT72041A (en)	1980-12-01
DE3068719D1 (en)	1984-08-30
CH650930A5 (de)	1985-08-30
JPS5686116A (en)	1981-07-13
GB2062468A (en)	1981-05-28
AU535357B2 (en)	1984-03-15
FI72045C (fi)	1987-04-13
IL61447A (en)	1983-11-30
HK40386A (en)	1986-06-06
ZA807005B (en)	1982-06-30
GB2062468B (en)	1983-08-24
AT371997B (de)	1983-08-25
ATA550480A (de)	1983-01-15
FI72045B (fi)	1986-12-31
MY8500165A (en)	1985-12-31
EP0028813B1 (de)	1984-07-25
DK155144C (da)	1989-07-03
PT72041B (en)	1982-01-26
IE50372B1 (en)	1986-04-02
EP0028813A2 (de)	1981-05-20
CY1332A (en)	1986-06-27
BE886008A (fr)	1981-05-04
GR72128B (da)	1983-09-16
IL61447A0 (en)	1980-12-31
DK477880A (da)	1981-05-13
DE2945636A1 (de)	1981-05-21
IE802340L (en)	1981-05-12
DK155144B (da)	1989-02-20

Publication	Publication Date	Title
JP7409772B2 (ja)	2024-01-09	ダントロレンを含む水性組成物
US4861786A (en)	1989-08-29	Composition for a stable vein compatible injectable solution of torasemide process for the preparation and method of use
EP1352654B1 (en)	2006-03-01	Famotidine injections
PL199846B1 (pl)	2008-11-28	Kompozycja farmaceutyczna dronedaronu do podawania pozajelitowego
US20080261939A1 (en)	2008-10-23	Stannsoporfin compositions and administration
US4402949A (en)	1983-09-06	Stable solutions of hydrogenated ergotalkaloids
JPH021126B2 (da)	1990-01-10
MXPA02009336A (es)	2003-01-28	Solucion parenteral que contiene amiodarona.
JPS605567B2 (ja)	1985-02-12	オキシテトラサイクリンの調合液
JPH10502628A (ja)	1998-03-10	長時間作用オキシテトラサイクリン組成物
AU2016346703B2 (en)	2020-07-02	Composition stably containing single-stranded nucleic acid molecule that suppresses expression of TGF-β1 gene
WO2012013117A1 (zh)	2012-02-02	含维生素c或其衍生物的替莫唑胺药物组合物及其制备方法
JP3720262B2 (ja)	2005-11-24	安定化したカルベジロール注射溶液
EP0365363B1 (en)	1993-04-14	Parenteral formulations of 1-diphenylmethyl-4-[(2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl]piperazine
JP4607761B2 (ja)	2011-01-05	溶液医薬組成物
WO2006107806A2 (en)	2006-10-12	Stannsoporfin compositions and administration
JPS6216929B2 (da)	1987-04-15
EP1508332A1 (en)	2005-02-23	Medicinal composition
HU190513B (en)	1986-09-29	Process for producing of new preparates consisting of hydrogenised ergot-alcaloids and hepharine with therapeutical effect
KR900002745B1 (ko)	1990-04-28	안정 주사용 진토제 조성물의 제조방법
JPH0296534A (ja)	1990-04-09	サイクロスポリンａ‐誘起腎毒性におけるトロンボキサンアンタゴニストの使用
WO1997005860A1 (fr)	1997-02-20	Solution aqueuse photostable contenant des derives de l'alcool benzylique
NO155428B (no)	1986-12-22	Fremgangsmaate for fremstilling av en stabil loesning av hydrogenerte ergotalkaloider.
JPH09104662A (ja)	1997-04-22	光に安定なベンジルアルコール誘導体含有水溶液
EA023081B1 (ru)	2016-04-29	Инъекционная лекарственная форма флупиртина